ALK抑制剂-话题@MedSci

#ALK抑制剂#

12篇内容 | 940人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2179700, encodeId=2a9021e97003e, content=<a href='/topic/show?id=211e823029d' target=_blank style='color:#2F92EE;'>#肺腺癌#</a> <a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a> <a href='/topic/show?id=3ae49e240b5' target=_blank style='color:#2F92EE;'>#间变性淋巴瘤激酶#</a>, objectTitle=KLC1/ALK重排肺腺癌胸膜转移患者对二三代ALK抑制剂原发耐药, objectType=article, longId=808529, objectId=0ac3808529ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-doctor-hand-with-pen-BWV9L2K.jpg, objectUrl=/article/show_article.do?id=0ac3808529ea, replyNumber=0, likeNumber=26, createdTime=2024-01-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0ac3808529ea, moduleTitle=KLC1/ALK重排肺腺癌胸膜转移患者对二三代ALK抑制剂原发耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ac3808529ea)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2178805, encodeId=d77321e8805e7, content=<a href='/topic/show?id=3c1ee4340c9' target=_blank style='color:#2F92EE;'>#神经母细胞瘤#</a> <a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a>, objectTitle=Cancer Cell：神经母细胞瘤新方案：靶向ALK的CAR T与ALK抑制剂联合治疗, objectType=article, longId=807598, objectId=df3380e598c1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016274166_4754896.png, objectUrl=/article/show_article.do?id=df3380e598c1, replyNumber=0, likeNumber=36, createdTime=2024-01-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=df3380e598c1, moduleTitle=Cancer Cell：神经母细胞瘤新方案：靶向ALK的CAR T与ALK抑制剂联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df3380e598c1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1442717, encodeId=6e6c1442e1795, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批, objectType=article, longId=725721, objectId=8aebe257213e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8aebe257213e, replyNumber=0, likeNumber=45, createdTime=2022-04-30, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8aebe257213e, moduleTitle=重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8aebe257213e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442716, encodeId=0ffb1442e16e6, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, objectType=article, longId=299456, objectId=55f52994568e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55f52994568e, replyNumber=0, likeNumber=46, createdTime=2022-02-24, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55f52994568e, moduleTitle=Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55f52994568e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442715, encodeId=abb61442e1590, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, objectType=article, longId=205805, objectId=fa1f20580549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa1f20580549, replyNumber=0, likeNumber=31, createdTime=2021-01-18, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa1f20580549, moduleTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa1f20580549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442714, encodeId=c43b1442e1495, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=国产ALK抑制剂恩沙替尼获批, objectType=article, longId=203601, objectId=b121203601f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b121203601f3, replyNumber=0, likeNumber=36, createdTime=2020-11-23, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b121203601f3, moduleTitle=国产ALK抑制剂恩沙替尼获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b121203601f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442713, encodeId=489c1442e13cb, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, objectType=article, longId=195930, objectId=68ef19593022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68ef19593022, replyNumber=0, likeNumber=40, createdTime=2020-06-17, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68ef19593022, moduleTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68ef19593022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442712, encodeId=d26d1442e125f, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=攻克脑转移——下一代ALK抑制剂的研发方向, objectType=article, longId=181404, objectId=d8111814040a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8111814040a, replyNumber=0, likeNumber=30, createdTime=2019-10-18, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8111814040a, moduleTitle=攻克脑转移——下一代ALK抑制剂的研发方向, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8111814040a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442711, encodeId=5c1b1442e11ce, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓, objectType=article, longId=180459, objectId=8e4a1804599f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e4a1804599f, replyNumber=0, likeNumber=40, createdTime=2019-10-05, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e4a1804599f, moduleTitle=【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e4a1804599f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442710, encodeId=de5c1442e1013, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=30, createdTime=2019-08-18, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442709, encodeId=e1151442e0916, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=CLIN CANCER RES：整合素β3阻滞可以增强ALK抑制剂抗肿瘤活性, objectType=article, longId=148809, objectId=3f8b1488090c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8b1488090c, replyNumber=0, likeNumber=42, createdTime=2018-09-15, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8b1488090c, moduleTitle=CLIN CANCER RES：整合素β3阻滞可以增强ALK抑制剂抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8b1488090c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442708, encodeId=62301442e08bb, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=Lancet Oncol述评：选择性ALK抑制剂可有效治疗ALK重排的非小细胞肺癌, objectType=article, longId=18826, objectId=71ba1882617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71ba1882617, replyNumber=0, likeNumber=49, createdTime=2013-05-18, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71ba1882617, moduleTitle=Lancet Oncol述评：选择性ALK抑制剂可有效治疗ALK重排的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71ba1882617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442707, encodeId=72581442e076a, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=STM：ALK抑制剂TAE-684能使ALK突变型神经母细胞瘤完全消退, objectType=article, longId=7786, objectId=fb5ee78639, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb5ee78639, replyNumber=0, likeNumber=40, createdTime=2012-07-13, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb5ee78639, moduleTitle=STM：ALK抑制剂TAE-684能使ALK突变型神经母细胞瘤完全消退, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb5ee78639)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1442706, encodeId=4c941442e06a9, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, objectTitle=赋予ALK抑制剂耐药性的肺癌中EML4-ALK突变, objectType=article, longId=2237, objectId=ee86223e41, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee86223e41, replyNumber=0, likeNumber=29, createdTime=2010-11-21, rootId=0, userName=12498cf9m36(暂无昵称), userId=68704968601, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee86223e41, moduleTitle=赋予ALK抑制剂耐药性的肺癌中EML4-ALK突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee86223e41)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALK抑制剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺腺癌# #ALK抑制剂# #间变性淋巴瘤激酶#

KLC1/ALK重排肺腺癌胸膜转移患者对二三代ALK抑制剂原发耐药

2024-01-06发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#神经母细胞瘤# #ALK抑制剂# #CAR-T#

Cancer Cell：神经母细胞瘤新方案：靶向ALK的CAR T与ALK抑制剂联合治疗

2024-01-02发表于上海

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批

2022-04-30

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

Oncologist：真实世界数据表明转移性ALK重排非小细胞肺癌(NSCLC)患者三线使用ALK抑制剂和化疗治疗无显著差异

2022-02-24

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤

2021-01-18

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

国产ALK抑制剂恩沙替尼获批

2020-11-23

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者

2020-06-17

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

攻克脑转移——下一代ALK抑制剂的研发方向

2019-10-18

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

【ESMO 2019】新型ALK抑制剂WX-0593片的I期研究结果揭晓

2019-10-05

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC

2019-08-18

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

CLIN CANCER RES：整合素β3阻滞可以增强ALK抑制剂抗肿瘤活性

2018-09-15

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

Lancet Oncol述评：选择性ALK抑制剂可有效治疗ALK重排的非小细胞肺癌

2013-05-18

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

STM：ALK抑制剂TAE-684能使ALK突变型神经母细胞瘤完全消退

2012-07-13

12498cf9m36(暂无昵称) (审核中...)

前往app查看评论内容

#ALK抑制剂#

赋予ALK抑制剂耐药性的肺癌中EML4-ALK突变

2010-11-21

科室
- - 订阅+
  - 更多科室
工具
服务